immuno-oncology

News

Pieris loses Servier as partner for cancer immunotherapies

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern.

News

Roche’s TIGIT drug linked to worse outcomes in NSCLC trial

Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of disappo

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

FDA clears BMS’ Breyanzi for follicular lymphoma

Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (

News

MSD has another TIGIT programme setback

A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi

News